Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Ruggiero

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Clinical, Cosmetic and Investigational Dermatology|March 26, 2024
The Past, the Present and the Future of Teledermatology: A Narrative ReviewNello Tommasino, Matteo Megna, Sara Cacciapuoti, et al.
Biomedicines|August 26, 2023
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current KnowledgeLuca Potestio, Teresa Battista, Sara Cacciapuoti, et al.
Clinical, Cosmetic and Investigational Dermatology|October 2, 2023
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat AreasSara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, et al.
Expert Opinion on Drug Safety|September 28, 2023
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluationLuca Potestio, Elisa Camela, Sara Cacciapuoti, et al.
Biomedicines|October 23, 2021
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?Matteo Megna, Sonia Sofia Ocampo-Garza, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology|December 26, 2022
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative ReviewAngelo Ruggiero, Fabrizio Martora, Gabriella Fabbrocini, et al.
Expert Opinion on Drug Safety|June 16, 2023
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluationAlessia Villani, Massimiliano Scalvenzi, Giuseppe Micali, et al.
Expert Opinion on Drug Safety|May 3, 2024
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluationLuca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Dermatology Practical & Conceptual|August 9, 2023
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD QuestionnaireElisa Camela, Alessia Villani, Sonia Sofia Ocampo Garza, et al.
Expert Opinion on Drug Safety|January 31, 2023
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patientsMatteo Megna, Elisa Camela, Teresa Battista, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Clinical, Cosmetic and Investigational Dermatology|March 26, 2024
The Past, the Present and the Future of Teledermatology: A Narrative ReviewNello Tommasino, Matteo Megna, Sara Cacciapuoti, et al.
Biomedicines|August 26, 2023
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current KnowledgeLuca Potestio, Teresa Battista, Sara Cacciapuoti, et al.
Clinical, Cosmetic and Investigational Dermatology|October 2, 2023
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat AreasSara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, et al.
Expert Opinion on Drug Safety|September 28, 2023
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluationLuca Potestio, Elisa Camela, Sara Cacciapuoti, et al.
Biomedicines|October 23, 2021
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?Matteo Megna, Sonia Sofia Ocampo-Garza, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology|December 26, 2022
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative ReviewAngelo Ruggiero, Fabrizio Martora, Gabriella Fabbrocini, et al.
Expert Opinion on Drug Safety|June 16, 2023
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluationAlessia Villani, Massimiliano Scalvenzi, Giuseppe Micali, et al.
Expert Opinion on Drug Safety|May 3, 2024
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluationLuca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Dermatology Practical & Conceptual|August 9, 2023
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD QuestionnaireElisa Camela, Alessia Villani, Sonia Sofia Ocampo Garza, et al.
Expert Opinion on Drug Safety|January 31, 2023
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patientsMatteo Megna, Elisa Camela, Teresa Battista, et al.
Pageof 8